<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
CYBN
Cybin
$
()


  • Cybin initiates CYB004 study

    3/15/2024 - 07:39am
  • Cybin announces end-of-Phase 2 meeting with FDA for CYB003

    3/14/2024 - 07:34am
  • Cybin receives FDA Breakthrough Therapy Designation for CYB003

    3/13/2024 - 06:02am
  • Here's What You Missed in Cannabis, Psychedelics This Week

    2/22/2024 - 11:19am
  • Cybin price target lowered by $1 at Canaccord, here's why

    2/22/2024 - 07:47am
  • Cybin reports Q3 net loss C$30.3M vs. C$10.7M last year

    2/14/2024 - 07:56am
  • Cybin granted two additional patents in Japan

    2/7/2024 - 07:38am
  • Here's What You Missed in Cannabis, Psychedelics This Week

    1/25/2024 - 11:09am
  • FDA clears Cybin IND application for CYB004 for GAD, begins Phase 2a in Q1

    1/23/2024 - 07:38am
  • Here's What You Missed in Cannabis, Psychedelics This Week

    1/11/2024 - 10:33am
  • Cybin: IM dosing of SPL028 produced robust, short-duration psychedelic effects

    1/8/2024 - 07:50am
  • Cybin anticipates end-of-Phase 2 meeting with FDA for CYB003 in Q1

    1/4/2024 - 07:37am
  • USPTO grants Cybin 'robust' patent protection for CYB003 program to treat MDD

    12/6/2023 - 07:36am
  • Cybin to discuss efficacy data for CYB003 for major depressive disorder

    11/30/2023 - 07:36am
  • Cybin initiated with a Buy at Alliance Global Partners

    11/20/2023 - 07:04am
dynamic_feed Breaking News